5414x May 2026

: £12.9 million (+27.4%), supported by synthetic biology.

Co-founder and CEO announced he will step down from his role and the board by the end of 2026. : £12

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. : £12.9 million (+27.4%)

"5414X" is the RNS (Regulatory News Service) identifier for the released by Oxford Nanopore Technologies plc . : £12

: £13.0 million (+52.9%), driven by AMR and EMEAI growth.

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .